Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
Charles River reports before the market opens, meaning Day 0 captures the first full trading session reaction to results, while Day +1 reflects follow-through momentum.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-08-05 | +$26.60 (+11.36%) | $15.92 (6.80%) | +$4.79 (+1.84%) | $12.21 (4.68%) |
| 2026-05-07 | -$0.05 (-0.03%) | $12.90 (7.10%) | -$4.06 (-2.23%) | $9.58 (5.27%) |
| 2026-02-18 | -$0.53 (-0.33%) | $12.12 (7.65%) | +$6.24 (+3.95%) | $13.81 (8.74%) |
| 2025-11-05 | -$10.15 (-5.71%) | $10.13 (5.70%) | +$3.18 (+1.90%) | $9.30 (5.55%) |
| 2025-08-06 | -$17.16 (-10.25%) | $12.44 (7.43%) | -$0.55 (-0.37%) | $5.46 (3.63%) |
| 2025-05-07 | +$21.56 (+18.68%) | $13.47 (11.67%) | +$4.39 (+3.21%) | $6.86 (5.01%) |
| 2025-02-19 | +$10.61 (+6.87%) | $11.29 (7.31%) | -$2.75 (-1.67%) | $6.55 (3.97%) |
| 2024-11-06 | +$25.52 (+13.53%) | $21.47 (11.38%) | -$3.91 (-1.83%) | $7.63 (3.56%) |
| Avg Abs Move | 8.34% | 8.13% | 2.12% | 5.05% |
Historical price behavior shows significant volatility around earnings, with an average absolute Day 0 move of 8.34% and typical intraday range of 8.13%. The most recent quarter produced an 11.36% surge on Day 0, the second-largest move in the dataset, followed by modest 1.84% follow-through on Day +1. Over the past eight quarters, Day 0 moves have ranged from -10.25% to +18.68%, with five positive reactions and three negative, indicating no clear directional bias but consistently large magnitude swings. Day +1 follow-through averages a more modest 2.12%, suggesting most of the price discovery occurs in the immediate reaction session. Investors should prepare for a potentially volatile response given the stock's recent 88% annual gain and elevated expectations around the margin expansion story.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 11/20/26 (DTE 17) |
| Expected Move | $36.08 (10.27%) |
| Expected Range | $315.20 to $387.36 |
| Implied Volatility | 70.26% |
The options market is pricing an expected move of 10.27% for the November 20 expiration, which is moderately above the 8.34% average historical Day 0 move but well within the range of recent outcomes. This suggests options traders are anticipating above-average volatility, consistent with the high stakes around biotech demand sustainability and margin expansion progress.
Part 3: What Analysts Are Saying
Analyst sentiment on Charles River is strongly bullish, with an average rating of 4.69 out of 5.00 (between Buy and Strong Buy). The current consensus includes 13 Strong Buy ratings, 1 Moderate Buy, and 2 Hold ratings, with zero sell recommendations. This represents an improved sentiment trend, as the average recommendation has strengthened from 4.65 one month ago, and the number of Moderate Buys declined from 2 to 1.
The mean price target of $320.93 implies 8.8% downside from the current price of $351.87, suggesting analysts believe the stock has run ahead of fundamentals despite their bullish ratings. The wide target range—from a low of $219.00 to a high of $357.00—reflects differing views on the pace and magnitude of margin expansion from the primate internalization initiative and biotech recovery. The high target of $357.00, set by UBS in its recent initiation, sits just 1.5% above current levels, indicating even the most optimistic analysts see limited near-term upside after the stock's 88% annual surge.
Part 4: Technical Picture
The Barchart Technical Opinion stands at 100% Buy, unchanged from both one week ago and one month ago, reflecting maximum bullish conviction in the technical setup. This sustained strength indicates the stock has maintained positive momentum despite recent volatility.
Timeframe Analysis:
- Short-term (100% Buy): Maximum buy signal indicates strong near-term momentum heading into earnings
- Medium-term (100% Buy): Continued strength in the intermediate timeframe supports the broader uptrend
- Long-term (100% Buy): Maximum bullish reading confirms the stock remains in a well-established long-term uptrend
Trend Characteristics: Maximum strength with a strengthening direction suggests the technical environment is highly supportive, though the stock's extended gains raise the stakes for a positive earnings surprise.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $359.98 | 50-Day MA | $303.84 |
| 10-Day MA | $354.59 | 100-Day MA | $270.10 |
| 20-Day MA | $328.54 | 200-Day MA | $223.02 |
CRL trades above its 20-day ($328.54), 50-day ($303.84), 100-day ($270.10), and 200-day ($223.02) moving averages, confirming the strength of the uptrend across all major timeframes. However, the stock sits below its 5-day ($359.98) and 10-day ($354.59) moving averages, indicating some near-term consolidation after the recent surge. The current price of $351.87 represents a 57.8% premium to the 200-day moving average, suggesting the stock is technically extended. While the overall setup remains supportive with all major trend indicators positive, the combination of stretched valuations, analyst price targets below current levels, and elevated options-implied volatility creates a high-risk, high-reward scenario heading into the November 4 report. A strong beat with positive 2027 guidance could propel the stock toward the $357 high target, but any disappointment on biotech demand or margin progress could trigger a sharp reversal given the extended technical position.